Assembly Biosciences Reports Director/Officer Changes & More

Ticker: ASMB · Form: 8-K · Filed: 2025-06-09T00:00:00.000Z

Sentiment: neutral

Topics: governance, officer-change, director-change

TL;DR

Assembly Bio's leadership shuffle is official; expect board changes and officer appointments.

AI Summary

Assembly Biosciences, Inc. filed an 8-K on June 9, 2025, reporting on events that occurred on June 5, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes information on matters submitted to a vote of security holders and financial statements and exhibits.

Why It Matters

This filing indicates potential shifts in leadership and governance at Assembly Biosciences, which could impact the company's strategic direction and operational management.

Risk Assessment

Risk Level: medium — Changes in directors and officers can signal strategic shifts or internal challenges, warranting closer monitoring.

Key Players & Entities

FAQ

What specific directors or officers have departed from Assembly Biosciences?

The filing indicates the departure of directors or certain officers, but does not name the specific individuals in the provided text.

Who has been elected as new directors for Assembly Biosciences?

The filing states that directors have been elected, but the names of the newly elected directors are not specified in the provided text.

Were there any new officer appointments at Assembly Biosciences?

Yes, the filing reports the appointment of certain officers, though their identities are not detailed in the excerpt.

What compensatory arrangements for officers are detailed in this filing?

The filing mentions compensatory arrangements of certain officers, but the specifics of these arrangements are not provided in the text.

Were any matters submitted to a vote of Assembly Biosciences' security holders?

Yes, the filing indicates that matters were submitted to a vote of security holders.

From the Filing

0000950170-25-083830.txt : 20250609 0000950170-25-083830.hdr.sgml : 20250609 20250609170014 ACCESSION NUMBER: 0000950170-25-083830 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250605 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250609 DATE AS OF CHANGE: 20250609 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 251034886 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 8-K 1 asmb-20250605.htm 8-K 8-K false 0001426800 0001426800 2025-06-05 2025-06-05     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       Two Tower Place , 7th Floor , South San Francisco , California 94080 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (833) 509-4583 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001   ASMB   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment No. 1 and Amendment No. 2 to Amended and Restated 2018 Stock Incentive Plan At the Assembly Biosciences, Inc. (the “Company”) Annual Meeting of Stockholders held on June 5, 2025 (the “Annual Meeting”), the Company’s stockholders approved Amendment No. 1 (“Amendment No. 1&#8

View on Read The Filing